Novel treatment of dermatitis using secreted factors derived from stem cells of human exfoliated deciduous teeth

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K08690
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53050:Dermatology-related
• Research Institution: The University of Tokushima
• Principal Investigator: HASHIMOTO Noboru 徳島大学, 大学院医歯薬学研究部(歯学域), 助教 (90712365)
• Co-Investigator(Kenkyū-buntansha): 加納 史也 徳島大学, 大学院医歯薬学研究部(歯学域), 助教 (40801626) ; 杉浦 一充 藤田医科大学, 医学部, 教授 (70335032)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: アトピー性皮膚炎 / 乳歯歯髄幹細胞 / Siglec-9 / T細胞

Outline of Final Research Achievements

We has reported that human deciduous dental pulp stem cell culture supernatant (SHED-CM) and its secreted Siglec-9 and other components improve the pathogenesis of various inflammatory diseases. In this research, administration of SHED-CM to a mouse model of atopic dermatitis (AD) with repeated Ovalbumin application improved skin pathology; SHED-CM administration significantly reduced T cells in the skin tissue. On the other hand, regulatory T cells (Treg) increased and IL-4 expression was suppressed, suggesting that Tregs suppress Th2 cells involved in AD pathology. LC/MS analysis of SHED-CM is being conducted to identify effectors.

Free Research Field

免疫学、糖鎖生物学

Academic Significance and Societal Importance of the Research Achievements

アトピー性皮膚炎の発症・進展のメカニズムは未解明な点が多く重篤な症状に対する有効な治療法は少ない。免疫抑制分子、細胞を効率よく誘導することができる手法は炎症性疾患の治療において重要な課題である。SHED-CMに含まれるsSiglec-9等のT細胞を標的としたAD病態改善効果とその詳細な分子機構が明らかになることは新たなT細胞制御機構の解明につながると考えている。さらにその知見を元にした抗炎症と再生の多面的な効果メカニズムは次世代のAD治療薬開発の情報基盤となることが期待される。